CPB Ljubljana 2018 course book

Overall survival

Local recurrence

APBI: 1.44% WBI: 0.92%

APBI: 97% WBI: 95%

No grade 4 late side-effects.

APBI WBI

5-year risk G2-3 late side-effects to the skin: 5-year risk of G2–3 late subcutaneous tissue :

3.2% 5.7% (p=0.08) 7.6% 6.3% (p=0.53) 0 0.2% (p=0.46)

Severe (G3) fibrosis at 5 years:

APBI using multicatheter brachytherapy can be regarded as a valid alternative treatment option after breast-conserving surgery and can be offered for all low-risk breast cancer patients in clinical routine.

Strnad V et al.Lancet. 2016 Jan 16;387(10015):229-38